As BioMarin Stumbles, Sanofi Gets Breakthrough Status For Hemlibra Challenger
US Filing Expected Shortly
Executive Summary
Sanofi and its partner Sobi believe they have the future “Factor VIII of choice” t could also challenge the dominance of Roche’s Hemlibra.
You may also be interested in...
Japan-Specific Approval For Hemlibra In Acquired Hemophilia A
Hemlibra receives new approval in Japan intractable disease indication, while positive Phase III results in mild/moderate disease hemophilia A will support a planned EU filing in this setting.
BioMarin Delays Resubmission, But Roctavian’s Rocky Road Winding Down
The company had planned to refile its application at the end of June, though it is gearing up for potential approval and commercialization in Europe that could provide important experience for the US.
Fitusiran Delay Dents Sanofi’s Hemophilia Challenge
New data show fitusiran’s promise across hemophilia A and B, but a switch to a lower dose prompted by safety concerns will delay its filing until 2024.